Chlorambucil is an oncological therapeutic compound whose cytotoxic mechanism—DNA alkylation, topoisomerase inhibition, antimitotic activity, or targeted kinase inhibition—produces tumour cell death or growth arrest at concentrations achievable clinically. The therapeutic index of Chlorambucil is narrow, with effective antitumour doses closely approaching doses producing unacceptable toxicity to normal host tissues. In pharmaceutical manufacturing, Chlorambucil is classified in the highest occupational hazard band based on its combination of pharmacological potency, genotoxic classification under ICH M7, and demonstrated systemic toxicity in preclinical and clinical studies.
The severe toxicity modifier F4 in PDE derivation for Chlorambucil is applied when the nature of the critical adverse effect warrants additional conservatism beyond the default interspecies and intraspecies uncertainty factors.
